Warning about dangerous consequences of use of Miracle Mineral Solution (MMS)
29.01.2016
more
News and Educations
Notice of temporary unavailability of HALMED's online applications and e-mail addresses
28.01.2016
more
Direct healthcare professional communication on the risks related to the effects of fingolimod (Gilenya) on the immune system
22.01.2016
more
PRAC News – January 2016
19.01.2016
more
Newly approved medicinal products
15.01.2016
The list of newly approved medicinal products for the period between 1st December 2015 and 31st December 2015 is available in the continuation of this notice.
more
Direct healthcare professional communication on the restriction of indication for treatment with Tarceva (erlotinib)
14.01.2016
more
Recommendations for reporting variations in medicinal product documentation based on the signal safety review from the PRAC December 2015 meeting
08.01.2016
more
Direct healthcare professional communication on the importance of following instructions for use of Genotropin (somatropin) to mitigrate potential defect in pre-filled pen device
04.01.2016
Pfizer Croatia d.o.o., in agreement with the Agency for Medicinal Products and Medical Devices (HALMED) has informed healthcare professionals on the importance of following instructions for use of Genotropin 5,3 mg powder and solvent for solution for injection and Genotropin 12 mg powder and solvent for solution for injection (somatropin) to mitigrate potential defect in pre-filled pen device.
more
Direct healthcare professional communication on the new safety information related to the hepatic safety of Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir)
04.01.2016
AbbVie d.o.o., in agreement with the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) and the European Medicines Agency (EMA), has informed healthcare professionals of important new safety information related to the hepatic safety of Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir).
more
